Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
5,053 total articles
Elizabeth C. Bogan, a director of Gabelli Dividend & Income Trust (NYSE: GDV), bought 400 shares of the trust on January 27, 2026, at $28.7299 per share for a total of $11,491, according to a Form 4 filed with the SEC. The trust also amended its Statement of Preferences to authorize an additional 10 million Series M Cumulative Term Preferred Shares…
Director Conn James P purchased 1,000 shares of Gabelli Dividend & Income Trust (NYSE: GDV) on January 27, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The trust also amended its Statement of Preferences to increase the authorized Series M Cumulative Term Preferred Shares by 10 million to a total of 30 million, and…
Horizon Kinetics Asset Management LLC reported the acquisition of one share of Texas Pacific Land Corp on January 27, 2026, at $339.86, retaining a roughly 10% stake with 3,487,700 shares owned. The disclosure arrives amid Texas Pacific Land's third-quarter 2025 earnings miss and the company’s announcement of a strategic partnership with Bolt Data …
Williams Gregg, a ten percent owner of Vivani Medical, acquired 1,351,351 shares at $1.48 apiece on January 27, 2026, in a private placement worth $1,999,999. The purchase coincided with a registered direct offering and follows an earlier at-market offering. Despite the insider buying, third-party data show financial strain at the company and analy…
An executive at Becton Dickinson & Company sold a small block of shares under a pre-established trading plan while the company announced a dividend, a share repurchase authorization and several product and strategic developments. The sale was executed under a Rule 10b5-1 plan and signed by an attorney-in-fact. Separately, the company disclosed a Ma…
Truist Financial Corp Chief Financial Officer Michael Baron Maguire sold 13,000 shares on January 26, 2026, generating $651,664 from transactions priced between $50.100 and $50.145. The bank's shares trade close to a 52-week high while recent quarterly results missed consensus and the company issued $1.25 billion in senior notes maturing in 2032.
Kelli D. Shomaker, a director at SmartFinancial Inc (NASDAQ: SMBK), purchased 255 shares on January 27, 2026, spending $10,041 and bringing her direct holdings to 1,022 shares. Separately, SmartFinancial reported fourth-quarter 2025 results that modestly outpaced analyst expectations on both earnings per share and revenue.
Goldman Sachs Group Inc. Chief Accounting Officer Sheara J. Fredman executed a sequence of sales on January 23, 2026, disposing of 4,800 shares of common stock for proceeds totaling $4,492,188, with transaction prices spanning $917.88 to $935.96. Fredman also reported a gift of 530 shares and now directly holds 10,311 shares. The company filing tha…
Richard Craig Smith, Senior Vice President at AutoZone Inc., sold 5,910 shares on January 23, 2026, realizing $21,867,000 at $3,700.00 per share after exercising options to acquire the same number of shares at $587.13. The company reported fiscal Q1 2026 EPS below consensus and has seen several analysts trim price targets amid margin pressures rela…
Patrick J. Heron, a director at Mirum Pharmaceuticals Inc (NASDAQ: MIRM), acquired 131,425 shares of the company’s common stock for $8,999,984 on January 23, 2026, and also gained 159,277 shares indirectly through a fund tied to the recent Bluejay Therapeutics merger. Mirum reported preliminary unaudited net product sales of about $520 million for …
Kathryn H. Ruemmler, Chief Legal Officer and General Counsel of Goldman Sachs Group Inc. (NYSE: GS), sold 9,129 shares on January 23, 2026, generating $8,893,930 in proceeds at prices between $921.91 and $935.79, according to a Form 4 filing. After the sale she owns 18,533 shares. The filing coincides with separate disclosures about CEO compensatio…
Catherine A. Lynch, a director at PennyMac Mortgage Investment Trust (NYSE: PMT), purchased 1,450.9361 common shares through automatic dividend reinvestment on January 23, 2026, spending $19,207 across two transactions. Separately, PennyMac Corp., an indirect wholly owned subsidiary, issued an additional $75 million of 8.5% Exchangeable Senior Note…
Protagonist Therapeutics CFO Asif Ali sold 46,203 shares on January 27, 2026, for about $3.8 million and exercised options to buy 28,000 shares the same day. PTGX shares are trading above InvestingPro's Fair Value estimate and near a 52-week high, while analysts have lifted price targets and flagged upcoming regulatory catalysts and earnings revisi…
Protagonist Therapeutics President and CEO Dinesh V. Patel sold 48,205 shares of the company between January 23 and January 27, 2026, for roughly $4.06 million, exercised options to acquire 48,273 shares and donated 6,000 shares on January 23. The transactions leave Patel with 574,505 shares. Multiple Wall Street firms have recently adjusted price …
Teresa Brophy Bair, Kura Oncology's chief legal officer, sold 11,208 shares on January 27, 2026 to satisfy tax obligations tied to prior RSU grants. The company also reported its first U.S. commercial sale of KOMZIFTI, triggering a $135 million payment from Kyowa Kirin expected before the end of 2025. Citizens reaffirmed its Market Outperform ratin…
Protagonist Therapeutics' Chief Medical Officer, Arturo Molina MD, sold 23,151 shares across three trades late January 2026 for about $1.9 million and exercised 10,000 options. The transactions were disclosed in a Form 4 filing and come amid a string of analyst price-target increases and maintained Buy/Outperform ratings tied to upcoming regulatory…
Thomas James Doyle, Kura Oncology's senior vice president of finance and accounting, sold 7,141 shares on January 27, 2026, realizing $60,426. The sale was completed to satisfy tax obligations tied to vested restricted stock units. The company has reported recent commercial progress with KOMZIFTI and retains positive analyst coverage while remainin…
Kura Oncology Chief Operating Officer Kathleen Ford sold 1,813 shares on January 27, 2026, to satisfy tax obligations tied to a 2022 restricted stock unit award. The transaction followed a sequence of corporate milestones for Kura, including the first U.S. commercial sale of KOMZIFTI, a $135 million milestone payment from partner Kyowa Kirin expect…
Mollie Leoni, chief medical officer at Kura Oncology, executed four stock sales on January 27, 2026, disposing of 8,182 shares for roughly $69,208 to meet tax liabilities from vested restricted stock units. The transactions occurred while Kura shares traded near $8.47, a level InvestingPro indicates sits below the stock's Fair Value despite a 36.72…
Kura Oncology Chief Scientific Officer Francis Burrows sold 1,311 shares on Jan. 27, 2026, at $8.4607 per share to satisfy tax obligations tied to an RSU vesting. The company meanwhile reported its first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment from partner Kyowa Kirin expected before the end of 2025.
Eric Sprott and an entity he controls purchased 100,000 Hycroft Mining Class A shares at $49.96 apiece on January 26, 2026, a $4,996,000 investment that raises his total holdings to 36,553,704 shares. The company has reported exceptional silver drill results at its Vortex system, eliminated all debt after raising $235 million in net proceeds, and c…
MDB Capital Holdings, LLC (NASDAQ: MDBH) reported two insider sales by Chief Financial Officer James Jeremy William on January 23 and January 26, 2026. The transactions, executed as sell-to-cover trades to satisfy tax withholding obligations from restricted stock vesting, totaled $11,621 and reduced William's direct stake to 19,839 shares. The comp…
Charles E Jobson, who holds a roughly 10% stake in The Joint Corp (NASDAQ: JYNT), bought 17,478 shares of the company in two SEC-reported transactions, spending $174,780 at $10.00 per share. The purchases came as the small-cap operator shows a stronger cash position than debt, posted an earnings beat in Q3 2025, and entered into an agreement to div…
Sheena Jonathan, co-founder of Natera, sold $365,914 of company shares on January 23, 2026, under a pre-arranged trading plan. The transactions involved shares held by Caraluna 1 Trust and Caraluna 2 Trust at prices between $242.232 and $245.62 per share. Separately, Natera reported preliminary fourth-quarter 2025 results showing near 40% revenue g…
Travere Therapeutics CEO Eric M. Dube sold 60,000 shares of common stock across transactions on January 23 and January 27, 2026, under a pre-arranged 10b5-1 program, generating roughly $1.8 million in proceeds. On the same dates he exercised options to acquire 60,000 shares at $15.46 each. Separately, the FDA has extended the review of Travere's su…
